Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
Central America, a region located between North and South America, has seen a steady growth in its pharmaceuticals market over the past few years.
Customer preferences: One of the primary drivers of this growth is the increasing demand for healthcare services in the region. With a growing population and an increase in the prevalence of chronic diseases, there is a greater need for pharmaceutical products. Additionally, the region's middle class is expanding, and with it, their purchasing power. This has led to a greater demand for higher quality and more expensive medications.
Trends in the market: Each country in Central America has its own unique pharmaceutical market, with varying trends. For example, in Guatemala, there has been a growing trend towards the use of generic drugs, as they are more affordable for the majority of the population. In contrast, in Costa Rica, there has been a greater demand for branded drugs, as the population has a higher disposable income.
Local special circumstances: One of the challenges facing the pharmaceutical market in Central America is the lack of regulation and oversight. This has led to a proliferation of counterfeit drugs, which can be dangerous for consumers. Additionally, there is a lack of investment in research and development, which has hindered the development of new and innovative drugs.
Underlying macroeconomic factors: Despite these challenges, there are several macroeconomic factors that are driving the growth of the pharmaceutical market in Central America. One of these is the increasing investment in healthcare infrastructure by governments in the region. This has led to a greater availability of healthcare services and an increase in demand for pharmaceutical products. Additionally, the region's proximity to the United States has led to an increase in foreign investment, which has helped to stimulate the market. Finally, the region's favorable trade agreements with the United States and other countries have made it an attractive location for pharmaceutical companies looking to expand their operations.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)